Top Day Trader Alerts (BIDU, PEP, MNKD, TM, AMLN, ALKS, BCON, ISPH)

Posted in Uncategorized 
March 15th, 2010

Baidu, Inc. (NASDAQ: BIDU) is running on word that Google is now much more likely than not about to close its China website.  At 8:45 AM EST we have seen 77,000 shares trade and the stock is up 3.8% at $571.43.  The old 52-week high is $559.47.

Pepsico, Inc. (NYSE: PEP) is trading higher at new 52-week highs.  This might not be a monster move but yet another 52-week high after it announced a share buyback plan of $15 billion and the dividend was raised by 7% to $1.92 from $1.80 per year.  Shares are up 1.5% at $66.03 as of 8:41 AM EST on thin volume.  The old 52-week high was $65.25 and Friday’s close was $65.10.

MannKind Corp. (NASDAQ: MNKD) is HALTED PENDING NEWS….. Stay tuned, this could be a big day of trading volume versus a 2.3 million share per day average.

Toyota Motor Corp. (NYSE: TM) is seeing a potential win today on news that regulators have been unable to reproduce the results from that recent runaway Prius and on word that the results are inconsistent with what had been described in the incident.

Amylin Pharmaceuticals, Inc. (NASDAQ: AMLN) is trading up despite an FDA on its once per week Byetta approval as a Type II diabetes drug.  The FDA is ok with its safety issues, but wants expanded data for labeling.  At 8:42 AM EST we have seen 750,000 shares trade hands and shares are up about 8.35% at $21.95.  This is not an approval, but it leans much closer to an approval compared to other FDA delays.  Keep in mind that the 52-week high is $21.58.

Alkermes, Inc. (NASDAQ: ALKS) is the technology behind the once per week absorption/delivery method for Amylin.  Its shares are up almost 11% at $13.55 on 125,000 shares as of 8:42 AM EST.

Beacon Power Corp. (NASDAQ: BCON) announced earnings and revenues this morning, but most important is that it said it needs to raise funds.  Unfortunately this is a penny stock. At 8:39 AM EST we have shares down 1.3% at $0.45 on 35,000 shares.

Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) is trading lower after its eye drug failed a mid-stage trial endpoint.  Shares closed at $7.06 on Friday, but the stock is down over 16% at $5.90 on 28,700 shares as of $8:46 AM EST.

You can join our free daily email distribution list to hear more about dividend trends, analyst upgrades and downgrades, top day trader and active trader alerts, news on Buffett and other investment gurus, IPOs, secondary offerings, private equity, and more.


Comments are closed